BioSpace News Archive

TEDOR Pharma, Inc., a full-service, end-to-end, contract development and manufacturing company (CDMO) founded in 2001, today announced the closing of a recapitalization and reorganization of its business, funded by investments from DORA Ventures, Inc.

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced the appointment of Bryan Giraudo to its Board of Directors. Mr. Giraudo currently serves as Chief Financial Officer of Gossamer Bio and was previously Senior Managing Director at Leerink Partners.

Multinational biotherapeutics company announces a new leadership team, expands its global footprint and advances an innovative portfolio of immune modulators for unmet medical needs

H1. illuminates the people and findings shaping the world of healthcare

Pi-Cardia Ltd., announced today that it recently started its First-in-Human study with its Leaflex(TM) Performer catheter system.

Company is pioneering a powerful new class of medicines - cell-penetrating miniproteins - with an on-demand drug discovery platform for the treatment of serious diseases driven by intractable targets

Plans to Seek FDA Guidance for Potential Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) Indication

Ms. Thomas will have responsibility for developing and leading Liquidia’s commercial plans, with initial focus on LIQ861, an inhaled dry powder formulation of treprostinil currently being evaluated in a pivotal Phase 3 safety trial for the treatment of pulmonary arterial hypertension.

Proceeds will accelerate the company’s global commercialization activities for the FDA-Cleared, Wireless CareTaker® Continuous “Beat by Beat” Non-Invasive Blood Pressure and Vital Signs monitor which enables untethered, continuous patient monitoring with a simple finger cuff.

Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced the publication of new preclinical research findings describing the potential utility of the Company’s most advanced cancer immunotherapy platform, selective RORgamma agonists, in adoptive cell therapy applications.